Generic Xenoview Availability
Last updated on Apr 10, 2025.
Xenoview is a brand name of xenon xe 129 hyperpolarized, approved by the FDA in the following formulation(s):
XENOVIEW (xenon xe-129 hyperpolarized - gas;inhalation)
-
Manufacturer: POLAREAN
Approval date: December 23, 2022
Strength(s): N/A [RLD]
Is there a generic version of Xenoview available?
No. There is currently no therapeutically equivalent version of Xenoview available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Xenoview. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Hyperpolarized noble gas production systems with nanocluster suppression, detection and/or filtering and related methods and devices
Patent 10,583,205
Issued: March 10, 2020
Inventor(s): Freeman Matthew S. & Driehuys Bastiaan
Assignee(s): Duke UniversitySystems, methods and related devices used to produce and collect polarized noble gas to inhibit, suppress, detect or filter alkali metal nanoclusters to preserve or increase a polarization level thereof. The systems can include a pre-sat chamber that has an Area Ratio between 20 and 500.
Patent expiration dates:
- February 20, 2035✓
- February 20, 2035
-
Hyperpolarized noble gas production systems with nanocluster suppression, detection and/or filtering and related methods and devices
Patent 11,052,161
Issued: July 6, 2021
Inventor(s): Freeman Matthew S. & Driehuys Bastiaan
Assignee(s): Duke UniversitySystems, methods and related devices used to produce and collect polarized noble gas to inhibit, suppress, detect or filter alkali metal nanoclusters to preserve or increase a polarization level thereof. The systems can include a pre-sat chamber that has an Area Ratio between 20 and 500.
Patent expiration dates:
- December 29, 2035✓
- December 29, 2035
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- December 23, 2027 - NEW CHEMICAL ENTITY
More about Xenoview (xenon xe 129 hyperpolarized)
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: diagnostic radiopharmaceuticals
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.